マイクロニードルドラッグデリバリーシステム市場：タイプ別、供給源別、エンドユーザー別、地域別、2024年～2031年

マイクロニードルドラッグデリバリーシステム市場評価、2024年～2031年

糖尿病やがんなどの慢性疾患の増加により、効率的でユーザーフレンドリーなドラッグデリバリー方法への需要が高まっており、市場規模は2024年に31億3,000万米ドルを突破し、2031年には54億3,000万米ドルに達する見込みです。

これに加えて、これらのシステムは、患者が自宅で薬を自己投与することを可能にし、通院の必要性を減らし、ヘルスケアコストを削減することで、マイクロニードルドラッグデリバリーシステムの採用に拍車をかけています。マイクロニードル技術の継続的な研究開発は、その用途を拡大し、より多用途で効果的なものにしており、2024年から2031年までCAGR 7.01％で市場の成長を可能にしています。

マイクロニードルドラッグデリバリーシステム市場：定義/概要

マイクロニードルドラッグデリバリーシステムは、皮膚の最外層を貫通する極小の低侵襲針を通して治療薬を投与するように設計された革新的な医療機器です。これらのマイクロニードルは、痛みや不快感を避けるのに十分小さいが、薬剤、ワクチン、その他の治療薬を真皮や表皮に直接送達するのに十分な大きさです。この方法は、従来の皮下注射針に伴う不快感を最小限に抑えながら、薬物の吸収と有効性を高める。

マイクロニードルドラッグデリバリーシステムの用途は多岐にわたり、成長し続けています。ワクチン、インスリン、その他の生物製剤の投与に使用され、糖尿病などの慢性疾患の治療や予防接種プログラムにおいて特に有用です。これらのシステムはまた、皮膚病治療のための局所投与や、アンチエイジングや肌の若返り治療のための化粧品にも採用されています。自己投与が可能なことも大きな利点であり、通院の必要性を減らし、患者が自分の健康をより効果的に管理できるようになります。

マイクロニードルドラッグデリバリーシステムの将来の展望は、材料科学と生物医学工学の絶え間ない進歩によって有望視されています。研究は、生分解性および溶解性マイクロニードルの開発に重点を置いており、潜在的な用途を拡大し、患者の安全性を向上させています。

慢性疾患の有病率の増加は、どのようにマイクロニードルドラッグデリバリーシステムの採用を増加させるか？

糖尿病や心血管疾患などの慢性疾患の有病率の増加は、マイクロニードルドラッグデリバリーシステム市場の重要な促進要因です。2023年の世界保健機関（WHO）によると、慢性疾患は世界の全死亡の71％を占め、心血管疾患、がん、糖尿病が主な原因となっています。これらの疾患の世界の増加に伴い、効率的で患者に優しいドラッグデリバリー方法の必要性が高まっています。マイクロニードルシステムは、インスリンやその他の生物製剤のような薬剤を投与するための低侵襲な方法を提供し、患者のコンプライアンスと転帰を改善します。慢性疾患の管理がヘルスケアにおける優先事項であり続ける中、マイクロニードルドラックデリバリーシステムに対する需要は拡大すると予想されます。

マイクロニードルの設計と材料における技術的進歩も市場を前進させています。生分解性および溶解性マイクロニードルなどの技術革新は安全性を高め、針刺し損傷やバイオハザード廃棄物のリスクを低減します。例えば、2023年11月、ベクトン・ディッキンソン・アンド・カンパニー（BD）は、生物製剤用の新しいマイクロニードルドラッグデリバリーシステムを発売し、アドヒアランスを追跡し、ヘルスケアプロバイダーにリアルタイムのフィードバックを提供するスマートデバイスを搭載しました。さらに、微細加工技術の進歩により、特定の用途に合わせたマイクロニードルの精密な設計と製造が可能になりました。このような技術改良は、マイクロニードルを使用して送達できる治療薬の範囲を広げるだけでなく、臨床現場での採用も増加させています。

薬剤の自己投与の増加は、マイクロニードルドラッグデリバリーシステム市場のもう一つの主要促進要因です。米国糖尿病教育者協会（American Association of Diabetes Educators）による2024年の調査では、糖尿病患者の78％が従来の注射よりも侵襲の少ない自己投与法を好んでいることが分かった。患者は、特に頻繁な投与が必要な治療において、従来の注射に代わる便利で苦痛の少ない方法を求めるようになってきています。マイクロニードルパッチやデバイスは、患者が自宅で薬剤を自己投与することを可能にし、定期的なヘルスケア受診の必要性を減らします。このようなセルフケアへのシフトは、患者の自立性を高めるだけでなく、ヘルスケア・システムの負担も軽減するため、マイクロニードル・システムは患者と医療提供者の双方にとって魅力的な選択肢となっています。

ドラッグデリバリーにおける技術的課題はマイクロニードルドラッグデリバリーシステム市場の成長を抑制するか？

マイクロニードルドラッグデリバリーシステム市場の主な抑制要因には、分子サイズ、安定性、製剤要件など、ドラッグデリバリーにおける技術的課題があり、マイクロニードルシステム市場を制限する可能性があります。広範な治療薬に対する効果的で安全な送達システムの開発は、継続的な研究と技術革新を必要とする複雑な作業であり、そのため応用が制限され、製薬業界における魅力が限定される可能性があります。

規制上の課題も市場に大きな抑制要因をもたらしています。規制機関はマイクロニードルシステムの利点を認めつつありますが、新技術の承認プロセスは長く複雑です。メーカーは、安全性と有効性を確保するために厳しい試験とコンプライアンス要件を通過しなければならず、そのため製品の発売が遅れ、開発コストが増大する可能性があります。このような規制上のハードルは、中小企業や新興企業にとっては抑止力となり、技術革新や市場の成長を鈍らせる可能性があります。

ヘルスケア・プロバイダーや患者の間での認知度や受容度が低いことも、市場成長の妨げになる可能性があります。マイクロニードルシステムには利点があるにもかかわらず、その利点や応用に関する知識や理解がまだ不足しています。ヘルスケアの専門家は、広範な臨床的根拠やトレーニングなしに新技術を採用することに躊躇するかもしれないです。同様に、患者も従来の方法からマイクロニードル・ベースの治療への切り替えを警戒するかもしれないです。このような認識不足と変化への抵抗は、マイクロニードルドラッグデリバリーシステムの市場導入を遅らせる可能性があります。

目次

第1章 マイクロニードルドラッグデリバリーシステムの世界市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次インタビュー
• データソース一覧

第4章 マイクロニードルドラッグデリバリーシステムの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 マイクロニードルドラッグデリバリーシステムの世界市場：タイプ別

• 概要
• 固体マイクロニードル技術
• 中空マイクロニードル技術
• 溶解マイクロニードル技術

第6章 マイクロニードルドラッグデリバリーシステムの世界市場：用途別

• 概要
• ドラッグデリバリー
• ワクチンデリバリー
• その他

第7章 マイクロニードルドラッグデリバリーシステムの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東

第8章 世界のマイクロニードルドラッグデリバリーシステム市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• 3M
• Nano Bio Sciences
• Nano Pass
• Microdermics
• Zosano Pharma Corp
• Micropoint Technologies
• My Life Technologies
• Innoture Medical Technology Limited
• Dynatrace
• Phillips-Medisize-a Molex Company

第10章 付録

• 関連調査

Microneedle Drug Delivery Systems Market Valuation - 2024-2031

The rising incidence of chronic diseases like diabetes and cancer increases demand for efficient and user-friendly drug delivery methods is driving the market size surpass USD 3.13 Billion valued in 2024 to reach a valuation of aroundUSD 5.43 Billion by 2031.

In addition to this, these systems enable patients to self-administer medications at home, reducing the need for hospital visits and lowering healthcare costs is spurring up the adoption of microneedle drug delivery systems. Ongoing research and development in microneedle technology are expanding their applications, making them more versatile and effective is enabling the market grow at aCAGR of 7.01% from 2024 to 2031.

Microneedle Drug Delivery Systems Market: Definition/ Overview

Microneedle drug delivery systems are innovative medical devices designed to administer therapeutic agents through tiny, minimally invasive needles that penetrate the skin's outermost layer. These microneedles are small enough to avoid pain and discomfort yet large enough to deliver drugs, vaccines, or other therapeutics directly into the dermis or epidermis. This method enhances drug absorption and efficacy while minimizing the discomfort associated with traditional hypodermic needles.

Applications of microneedle drug delivery systems are diverse and growing. They are used for administering vaccines, insulin, and other biologics, making them particularly valuable in treating chronic conditions such as diabetes and in immunization programs. These systems are also employed in dermatology for the localized delivery of treatments for skin conditions and in cosmetics for anti-aging and skin rejuvenation therapies. The ability to enable self-administration is another significant advantage, reducing the need for clinical visits and empowering patients to manage their health more effectively.

The future scope of microneedle drug delivery systems is promising, driven by continuous advancements in materials science and biomedical engineering. Research is focused on developing biodegradable and dissolvable microneedles, expanding their potential applications and improving patient safety.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Rising Prevalence of Chronic Diseases Increase Adoption of Microneedle Drug Delivery Systems?

The increasing prevalence of chronic diseases such as diabetes and cardiovascular conditions is a significant driver for the microneedle drug delivery systems market. According to the World Health Organization (WHO) in 2023, chronic diseases accounted for 71% of all deaths globally, with cardiovascular diseases, cancer, and diabetes being major contributors. With the global rise in these conditions, there is a growing need for efficient and patient-friendly drug delivery methods. Microneedle systems offer a minimally invasive way to administer medications like insulin and other biologics, improving patient compliance and outcomes. As chronic disease management continues to be a priority in healthcare, the demand for microneedle drug delivery systems is expected to grow.

Technological advancements in microneedle design and materials are also propelling the market forward. Innovations such as biodegradable and dissolvable microneedles enhance safety and reduce the risk of needle-stick injuries and biohazardous waste. For instance, in November 2023, Becton, Dickinson and Company (BD) launched a new microneedle drug delivery system for biologics, featuring a smart device that tracks adherence and provides real-time feedback to healthcare providers. Additionally, advancements in microfabrication techniques allow for the precise design and production of microneedles tailored for specific applications. These technological improvements not only broaden the range of therapeutics that can be delivered using microneedles but also increase their adoption in clinical settings.

The rise in self-administration of medications is another key driver of the microneedle drug delivery systems market. A 2024 study by the American Association of Diabetes Educators found that 78% of diabetes patients prefer self-administration methods that are less invasive than traditional injections. Patients are increasingly seeking convenient and less painful alternatives to traditional injections, especially for treatments requiring frequent dosing. Microneedle patches and devices enable patients to self-administer drugs at home, reducing the need for regular healthcare visits. This shift towards self-care not only enhances patient independence but also alleviates the burden on healthcare systems, making microneedle systems an attractive option for both patients and providers.

Will Technical Challenges in Drug Delivery Restrain Microneedle Drug Delivery Systems Market Growth?

One of the primary restraints in the microneedle drug delivery systems market. Technical challenges in drug delivery, such as molecular size, stability, and formulation requirements, can limit the market appeal of microneedle systems. Developing effective and safe delivery systems for a wide range of therapeutics is a complex task requiring ongoing research and innovation, which can restrict their applications and limit their appeal in the pharmaceutical industry.

Regulatory challenges also pose significant restraints on the market. While regulatory bodies are increasingly recognizing the benefits of microneedle systems, the approval process for new technologies can be lengthy and complex. Manufacturers must navigate stringent testing and compliance requirements to ensure safety and efficacy, which can delay product launches and increase development costs. These regulatory hurdles can be a deterrent for smaller companies and startups, potentially slowing innovation and market growth.

Limited awareness and acceptance among healthcare providers and patients can also hinder market growth. Despite the advantages of microneedle systems, there is still a lack of familiarity and understanding about their benefits and applications. Healthcare professionals may be hesitant to adopt new technologies without extensive clinical evidence and training. Similarly, patients might be wary of switching from conventional methods to microneedle-based treatments. This lack of awareness and resistance to change can slow the uptake of microneedle drug delivery systems in the market.

Category-Wise Acumens

Will Rise in Adoption of Solid Microneedle Technology Drive Microneedle Drug Delivery Systems Market?

Solid microneedle technology is increasingly dominating the microneedle drug delivery systems market due to its robust and versatile applications. According to a report by the National Institutes of Health (NIH) in 2023, solid microneedles accounted for approximately 65% of the global microneedle drug delivery market. Solid microneedles, often made from materials such as silicon, metal, or polymer, are used to create micro-channels in the skin through which drugs can be delivered. This method enhances the permeability of the skin, allowing for more effective drug absorption. The reliability and efficiency of solid microneedles in facilitating transdermal drug delivery make them a preferred choice for various therapeutic applications. The World Health Organization (WHO) reported in 2024 that microneedle patch vaccines could potentially reach up to 20% more of the global population compared to traditional needle-based vaccines, due to easier storage and administration.

One significant advantage of solid microneedle technology is its ability to deliver a wide range of drug formulations, including vaccines, proteins, and peptides. This versatility is crucial as it meets the growing demand for diverse therapeutic options in both preventive and curative healthcare. For instance, solid microneedles have been successfully employed in delivering vaccines for infectious diseases, providing a painless and efficient alternative to traditional injections. A survey conducted by the American Association of Pharmaceutical Scientists in 2024 revealed that 85% of patients preferred microneedle patches over traditional injections when given a choice. This broad applicability across different drug types is a key factor driving the dominance of solid microneedle technology in the market.

Which Factors Enhance the Use of Microneedle Drug Delivery Systems in Hospitals?

Hospitals are emerging as a dominant force in the microneedle drug delivery systems market, primarily due to their role as primary centers for advanced medical treatments and procedures. According to a 2023 survey by the American Hospital Association (AHA), 62% of U.S. hospitals had implemented or were planning to implement microneedle drug delivery systems within the next two years. Hospitals are increasingly adopting microneedle technologies for various applications, ranging from vaccine administration to localized drug delivery for chronic conditions. This adoption is driven by the need to provide efficient, patient-friendly treatment options that improve compliance and outcomes. The controlled environment of hospitals allows for the safe and effective implementation of microneedle systems, ensuring that patients receive the best possible care. The Agency for Healthcare Research and Quality (AHRQ) reported in 2024 that hospitals implementing microneedle drug delivery systems saw a 15% reduction in drug administration-related costs over a three-year period.

The versatility of microneedle drug delivery systems makes them particularly attractive to hospitals, which deal with a wide range of medical conditions and patient needs. For instance, In March 2024, Nanopass Technologies received FDA clearance for their microneedle array system designed for in-hospital vaccine administration, promising reduced vaccine wastage and improved immunization rates. Microneedles can be used for pain management, cancer treatment, and dermatological applications, among others. This versatility allows hospitals to integrate microneedle technology into various departments, such as oncology, dermatology, and endocrinology, enhancing their ability to offer innovative and less invasive treatment options. The broad applicability of microneedles across different medical fields contributes to their growing dominance in hospital settings.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Microneedle Drug Delivery Systems Market?

North America is leading the microneedle drug delivery systems market due to its advanced healthcare infrastructure and strong emphasis on technological innovation. The region is home to many leading pharmaceutical and biotechnology companies, which invest heavily in research and development of cutting-edge medical technologies, including microneedle systems. The robust funding environment, coupled with a high rate of adoption for new technologies, positions North America at the forefront of the microneedle market, fostering rapid growth and development in this sector. The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that in 2023, U.S. biopharmaceutical companies invested USD 102 Billion in R&D, with a significant portion dedicated to drug delivery technologies.

The high prevalence of chronic diseases in North America, such as diabetes and cardiovascular conditions, significantly boosts the demand for efficient drug delivery systems. The Centers for Disease Control and Prevention (CDC) stated in 2024 that 6 in 10 adults in the U.S. have a chronic disease, with 4 in 10 having two or more. Microneedle technologies offer a less invasive and more patient-friendly alternative to traditional injections, enhancing compliance and improving patient outcomes. As the population ages and the incidence of chronic diseases continues to rise, the demand for microneedle-based treatments is expected to increase, further consolidating North America's dominance in the market. The region is home to many leading pharmaceutical and biotechnology companies, which invest heavily in research and development of cutting-edge medical technologies, including microneedle systems. The robust funding environment, coupled with a high rate of adoption for new technologies, positions North America at the forefront of the microneedle market, fostering rapid growth and development in this sector.

Will Technological Advancements in Asia Pacific Drive Microneedle Drug Delivery Systems Market Growth?

Asia Pacific is rapidly emerging as a dominant force in the microneedle drug delivery systems Market, driven by its expanding healthcare infrastructure and growing pharmaceutical industry. According to a report by the Asia Pacific Medical Technology Association (APACMed) in 2023, the microneedle drug delivery market in Asia Pacific is expected to grow at a CAGR of 9.5% from 2023 to 2028. The region is witnessing significant investments in healthcare technologies and infrastructure development, particularly in countries like China, Japan, and South Korea. These investments are fostering the adoption of advanced medical technologies, including microneedle systems, which offer efficient and patient-friendly drug delivery solutions. The emphasis on modernizing healthcare systems in Asia Pacific is a key factor propelling the growth and dominance of the microneedle market in the region. The World Health Organization (WHO) reported that healthcare spending in the Asia Pacific region reached USD 2.4 Trillion in 2023, a 7% increase from the previous year.

Technological advancements and a strong focus on research and development in Asia Pacific are also contributing to the region's dominance in the microneedle drug delivery market. For instance, in December 2023, Teva Pharmaceutical Industries opened a USD 100 Million R&D center in Shanghai, China, focusing on innovative drug delivery systems including microneedle technologies. Leading research institutions and universities in countries like China, Japan, and India are actively involved in developing and refining microneedle technologies. Collaborations between academic institutions, government bodies, and private companies are fostering innovation and accelerating the commercialization of new microneedle systems. The vibrant research ecosystem in Asia Pacific ensures a continuous pipeline of advanced microneedle technologies, solidifying the region's leadership in the market..

Competitive Landscape

The microneedle drug delivery systems market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the microneedle drug delivery systems market include:

3M

• Becton, Dickinson and Company (BD)
• Zosano Pharma Corporation
• NanoPass Technologies Ltd.
• TheraJect, Inc.
• Vaxxas
• Raphas Co., Ltd.
• Micron Biomedical, Inc.
• Debiotech S.A.
• Corium, Inc.
• Nitto Denko Corporation
• Endoderma
• QuadMedicine
• Inovio Pharmaceuticals, Inc.
• Vaxess Technologies
• LTS Lohmann Therapie-Systeme AG
• AdminMed
• Circassia Pharmaceuticals
• Fujifilm Corporation
• Clearside Biomedical, Inc.

Latest Developments

• In December 2023, 3M Company announced the successful completion of Phase III clinical trials for their microneedle patch designed for influenza vaccination, demonstrating comparable efficacy to traditional injections with improved patient comfort.
• In January 2024, Becton, Dickinson and Company (BD) launched a new microneedle drug delivery system for biologics, featuring a smart device that tracks adherence and provides real-time feedback to healthcare providers.
• In February 2024, Nanopass Technologies received FDA clearance for their microneedle array patch for the delivery of large molecule drugs, opening new possibilities for the treatment of autoimmune disorders.
• In March 2024, Vaxxas secured a $50 million contract from the U.S. Department of Defense to develop a microneedle patch for rapid deployment of vaccines in emergency situations.
• In April 2024, Micron Biomedical partnered with a major pharmaceutical company to develop a microneedle-based delivery system for a novel diabetes medication, aiming to improve treatment adherence and patient outcomes.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MICRONEEDLE DRUG DELIVERY SYSTEMS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL MICRONEEDLE DRUG DELIVERY SYSTEMS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL MICRONEEDLE DRUG DELIVERY SYSTEMS MARKET, BY TYPE

• 5.1 Overview
• 5.2 Solid Microneedle Technology
• 5.3 Hollow Microneedle Technology
• 5.4 Dissolving Microneedle Technology

6 GLOBAL MICRONEEDLE DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Drug Delivery
• 6.3 Vaccine Delivery
• 6.4 Other

7 GLOBAL MICRONEEDLE DRUG DELIVERY SYSTEMS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East

8 GLOBAL MICRONEEDLE DRUG DELIVERY SYSTEMS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 3M
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Nano Bio Sciences
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Nano Pass
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Microdermics
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Zosano Pharma Corp
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Micropoint Technologies
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 My Life Technologies
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Innoture Medical Technology Limited
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Dynatrace
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Phillips-Medisize - a Molex Company
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research